Their half-life ranges from 24 hours (short-acting agents such as exenatide, lixisenatide) to 57 days (long-acting agents such as liraglutide, dulaglutide, semaglutide)
Int J Mol Sci 22(19):10637 Krauss Z, Hintz A, Fisk R (2023) Tirzepatide: clinical review of the twincretin injectable
Watching puppies play with gusto
While this medication produces substantial weight lossaveraging 15-22% of initial body weight in clinical trialspatients and providers often question whether tirzepatide causes muscle loss alongside fat reduction
Physical activity helps raise HDL cholesterol, which is the good kind of cholesterol, and lowers LDL cholesterol, the bad kind
To facilitate the clinical integration of emerging biomarkers in MASLD diagnosis and management, a flowchart summarizing the proposed stepwise implementation ranging from initial clinical assessment to biomarker-guided monitoring is presented in Figure 4